Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$46.09M$46.09M+1,689.8% vs Q2 2018 Net Income$11.15M$11.15MN/M vs Q2 2018 EPS Diluted$0.29$0.29N/M vs Q2 2018 Operating Income$9,189,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$33,621,000N/M Margins · derivedOperating margin19.9%+1017.8 pt vs Q2 2018
Net margin24.2%+1016.1 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end